http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101087614-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2008-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101087614-B1 |
| titleOfInvention | Pharmaceutical composition for treatment of BCN-resistant polymorphic glioblastoma, comprising RHE-1-1 specific siRNA as an active ingredient |
| abstract | The invention BCNU (1,3-Bis (2- chloroethyl) -1-nitrosourea, Carmustine) - resistance polymorphism glioblastoma therapy relates to a pharmaceutical composition, in particular stem cell marker of Rex-1 (r educed ex pression It relates to a pharmaceutical composition that induces apoptosis and tumor growth inhibition of BCNU-resistant polymorphous glioblastoma by including siRNA specific to Rex-1 as an active ingredient that inhibits the expression of -1). The pharmaceutical composition of the present invention can be usefully used for the treatment of BCNU-resistant polymorphic glioblastoma by co-administration with the BCNU.n n n n BCNU-resistant polymorphic glioblastoma, Rex-1, siRNA |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10208309-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015152693-A3 |
| priorityDate | 2008-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 270.